Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study

D. Ferone1 · E. Profka2 · V. Gasco3 · M. R. Ambrosio4 · A. Colao5 · C. Di Somma6 · E. Puxeddu7 · G. Arnaldi8 · C. Pagano9 · E. Zecchi10 · A. Pietropoli11 · P. Beck-Peccoz12

Received: 10 October 2016 / Accepted: 23 December 2016 / Published online: 4 February 2017 © The Author(s) 2017. This article is an open access publication

Abstract

Purpose To report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope®, a somatropin biosimilar to Genotropin®, in Italian patients with growth hormone deficiency (GHD) enrolled in the PATRO Adults study.

Methods The PATRO Adults study is an ongoing observational, longitudinal, non-interventional global post-marketing surveillance study, conducted in several European countries. The primary endpoint is long-term safety; secondary endpoints include the effectiveness of Omnitrope®, which was assessed using serum insulin-like growth factor-1 levels, body composition, bone mineral density and lipid levels. Here we report the data from the Italian patients enrolled in the study.

Results Sixty-seven patients (mean age 50.4 years, 61.2% male) have been enrolled and have received a mean 45.4 ± 24.3 months of Omnitrope®. A total of 55.2% of patients were reported to have experienced adverse events (AEs), including arthralgia, myalgia, abdominal distension and hypoaesthesia, and 4.5% had adverse drug reactions. Fourteen serious AEs have been recorded; none of these are considered related to the study drug. The effectiveness of Omnitrope® was similar to other available somatropin preparations.

Conclusions This study confirms the effectiveness and safety of Omnitrope® in adult patients with GHD in Italy. However, due to the limited size of the study population,

The Figures 1 and 3 were wrongly switched in the original version. They have been fixed and original version is updated.

D. Ferone
ferone@unige.it

1 Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research (CEBR), IRCCS AOU San Martino-IST, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy
2 Endocrinology and Metabolic Diseases Unit, Department of Clinical Sciences and Community Health, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, University of Milano, Milan, Italy
3 Endocrinology, Diabetes and Metabolism, Department of Medical Science, Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy
4 Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
5 Department of Clinical Medicine and Surgery, University Federico II of Napoli, Naples, Italy
6 Institute of Diagnostic and Nuclear Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico SDN, Naples, Italy
7 Veterinary and Forensic Biotechnological Sciences Department of Medicine Section, Internal Medicine, Endocrine and Metabolic Sciences, University of Perugia, Perugia, Italy
8 Clinica di Endocrinologia e Malattie del Metabolismo, Ospedali Riuniti di Ancona, Ancona, Italy
9 Department of Medicine, Internal Medicine 3, University of Padova, Padua, Italy
10 Sandoz S.p.A., Origgio, VA, Italy
11 Hexal AG, Holzkirchen, Germany
12 Endocrinology and Diabetology Unit, Medical Sciences Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

© Springer
these results need to be further confirmed by the global PATRO Adults study.

Keywords Growth hormone deficiency · Hypopituitarism · Omnitrope® · Recombinant human growth hormone · Insulin-like growth factor-1 · Safety

Introduction

Adult-onset growth hormone deficiency (GHD) is a condition associated with abnormal substrate metabolism, body composition, and physical and psychosocial function, due to the inability of the pituitary gland to produce enough growth hormone (GH) [1]. Consequently, patients with adult-onset GHD have difficulties in controlling their body weight, show increased body fat (more specifically abdominal fat), and decreased muscle mass with reduced muscle strength and exercise capacity. Increased anxiety levels and depressed mood also contribute to a reduced quality of life in these patients. Adult-onset GHD can result from hypothalamic-pituitary disease, neurosurgery and/or cranial irradiation during the treatment of pituitary and brain tumours, or traumatic brain injuries [2].

Guidelines for the diagnosis and treatment of adults with GHD recommend replacement therapy with recombinant human GH (rhGH), which is dosed based on plasma insulin-like growth factor-1 (IGF-1) levels and the presence or absence of side effects [1, 3]. Replacement therapy has been shown to correct the metabolic, functional and psychological abnormalities associated with adult GHD [4]. Lipolysis is increased in response to rhGH replacement therapy, resulting in a reduction of total body (mainly visceral) fat, while one year of rhGH therapy seems to reduce early cardiac organ damage in adult patients with GHD [5]. It has also been suggested that exercise capacity and physical performance can be improved by this treatment [1, 3].

One rhGH available for the treatment of GHD in adults is Omnitrope® (Sandoz, Kundl, Austria). Omnitrope®, expressed by a transformed strain of Escherichia coli, is biosimilar to Genotropin® (Pfizer Limited, Sandwich, UK) and was the first product to be approved by the European Medicines Agency (EMA) in 2006 using the European biosimilar regulatory pathway [6].

In adults, Omnitrope® is approved for the replacement of adult- or childhood-onset GHD. Studies in adult patients suggest that switching from Genotropin® to Omnitrope® has no impact on the safety and efficacy profile [7, 8]; however, data assessing the long-term safety and effectiveness of Omnitrope® in adults in the setting of routine clinical practice are not yet available. To address this, the Patients TReated with Omnitrope® (PATRO) Adults study was initiated as part of the Omnitrope® Active Pharmacovigilance Program agreed with the EMA upon the approval of Omnitrope®. PATRO Adults is a long-term post-marketing surveillance (PMS) study investigating the long-term safety and effectiveness of Omnitrope® in adults with GHD. It is being conducted as part of the Risk Management Plan for Omnitrope®, to fulfil the commitment with the EMA [9]. Preliminary results of this study indicate that Omnitrope® is well tolerated in routine clinical practice [10–12]. Between September 2007 and September 2015, 954 patients from eight different countries (Czech Republic, France, Germany, Italy, Spain, Sweden, The Netherlands, and UK) were enrolled in the PATRO Adults study. Here we report the results of all patients enrolled in Italy.

Materials and methods

Study design

PATRO Adults is a multicentre, open-label, longitudinal, non-interventional PMS study, which was initiated in September 2007 and is being conducted in hospitals and specialised endocrinology centres in various countries where Omnitrope® is approved and regularly prescribed. The design and methods of this study have been published in detail previously [9]. Briefly, eligible patients are adults (≥15 years old) receiving treatment with Omnitrope® for GHD (isolated or combined with other hormone deficiencies) and who provided written informed consent. Patients who had received a previous rhGH were also eligible for inclusion. The study was reviewed and approved by each study site’s Independent Ethics Committee or Institutional Review Board before the starting and was conducted in accordance with the Declaration of Helsinki.

Treatment and outcomes

Patients included in the PATRO Adults study received Omnitrope® treatment in accordance with the recommendations in the Summary of Product Characteristics [13] and/or the prescribing information of the respective countries. The primary objective of this PMS study was to collect and analyse data on the long-term safety of Omnitrope® in adults treated within routine clinical practice to extend the global safety database of Omnitrope®. Aspects of clinical safety, such as risk of developing glucose intolerance or diabetes and occurrence of malignancies, were examined along with the effects on cardiovascular risk factors, such as blood pressure and inflammatory markers. All adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and serious adverse drug reactions (SADRs) were collected and recorded in electronic case report forms (e-CRF) and entered into the Sandoz Safety Database.
The secondary objective was to monitor the treated population and to collect data on effectiveness issues related to Omnitrope® treatment. These included measurements of IGF-1 levels within age-and gender-adjusted normal ranges, and the fasting lipid profile. Body composition assessment was carried out using anthropometric measures (weight, waist and hip circumferences, total fat mass, lean body mass and body mass index [BMI]). All evaluations and assessments were performed at each local centre, according to the local practice.

Statistical analysis

The safety analysis set (SAF) included all patients who had documentation of any data in an e-CRF whilst the effectiveness analysis set (EFF) included all patients who had at least one dose of Omnitrope®. Statistical analyses for this study were performed using the software package SAS (version 9.3).

All AEs were coded using MedDRA version 17.1. Concomitant medication was coded according to WHO Drug Dictionary (version 14.3) and the medications were tabulated by Anatomical Therapeutic Chemical term in their current version. For continuous/quantitative variables, descriptive statistics including the number of data values available, number of data values missing, arithmetic mean, standard deviation, median and maximum were calculated. When appropriate, continuous parameters were compared using t tests or Wilcoxon non-parametric tests. For categorical/qualitative variables, frequency and percentage tables were generated. When appropriate, categorical data were compared using Chi-square or Fisher exact tests. Statistical tests were two sided at the significance level of 0.05.

Results

As of August 2015, 67 patients (mean age 50.4 years, 61.2% male) had been enrolled from eight sites in Italy (Table 1) and received a mean 45.4 ± 24.3 months of Omnitrope® treatment. Of these, 15 patients (22.4%) had discontinued treatment at the time of analysis; reasons for discontinuation included: patients did not wish to continue injections \(n=2\); 13.3%), AEs \(n=1\); 6.7%), referral to another endocrinologist \(n=1\); 6.7%), non-compliance \(n=1\); 6.7%) and loss to follow-up \(n=2\); 13.3%). The reason for discontinuation of Omnitrope® was unknown in the remaining eight patients (53.3% of discontinued patients). Overall, 31.3% of patients had received another rhGH before Omnitrope®. The mean duration of rhGH pre-treatment was 7.45 ± 4.97 (range 1.6–17.3) years.

| Characteristic                              | N=67  |
|---------------------------------------------|-------|
| Gender, \(n\) (%)                          |       |
| Male                                        | 41 (61.2) |
| Female                                      | 26 (38.8) |
| Age, years                                 | 50.4 ± 14.5 |
| Age group, \(n\) (%)                       |       |
| <25 years                                   | 4 (6.0) |
| 25–65 years                                 | 56 (83.6) |
| >65 years                                   | 7 (10.4) |
| BMI, kg/m²                                  | 28.9 ± 5.6 |
| Hip circumference, cm                      | 104.5 ± 18.3 |
| Waist circumference, cm                    | 94.6 ± 14.4 |
| Diagnosis at presentation, \(n\) (%)        |       |
| Isolated GHD                                | 9 (13.4) |
| Combined GHD                                | 58 (86.6) |
| Onset of puberty, \(n\) (%)†                |       |
| Normal                                      | 41 (61.2) |
| Late                                        | 9 (13.4) |
| Onset of GHD                                |       |
| Childhood onset                            | 8 (11.9) |
| Adulthood onset                            | 59 (88.1) |
| Family history of GHD, \(n\) (%)            |       |
| No                                          | 43 (64.2) |
| Unknown                                     | 24 (35.8) |
| Family history of diabetes, \(n\) (%)       |       |
| No                                          | 42 (62.7) |
| Yes                                         | 9 (13.4) |
| Unknown                                     | 16 (23.9) |
| Family history of autoimmune disease, \(n\) (%) |       |
| No                                          | 44 (65.7) |
| Yes                                         | 2 (3.0) |
| Unknown                                     | 21 (31.3) |
| Family history of other relevant disease, \(n\) (%) |       |
| No                                          | 30 (44.8) |
| Yes                                         | 22 (32.8) |
| Unknown                                     | 15 (22.4) |
| Previous treatment status, \(n\) (%)        |       |
| Treatment naïve                             | 46 (68.7) |
| Pre-treated                                 | 21 (31.3) |
| Concomitant medication for combined GHD patients |     |
| Levothyroxine sodium                        | 51 (78.9) |
| Cortisone acetate                           | 40 (69.0) |
| Colecalciferol                              | 28 (48.3) |
| Testosterone                                | 19 (32.8) |
| Desmopressin acetate                        | 15 (25.9) |
| Testosterone undecanoate                    | 13 (22.4) |
| Acetylsalicylic acid                        | 9 (15.5) |
| Hydrocortisone                              | 7 (12.1) |
| Simvastatin                                 | 7 (12.1) |
| Omnitrope® dosing at baseline, mg/kg/day    | 0.22 ± 0.11 |
Safety

As of August 2015, in the current Italian analysis, 89 AEs had been reported in 37 (55.2%) of the 67 patients included in the SAF (Table 2). The most common AEs reported were arthralgia, asthenia and insomnia. A total of six suspected ADRs were reported in three (4.5%) patients and included two arthralgia, two myalgia events, one event of abdominal distension and one of hypoesthesia. A total of 14 SAEs in 10 (14.9%) patients were reported; however, none were suspected to be related to the study drug. One patient developed a basal cell carcinoma after 2 years of rhGH replacement therapy, but this was not considered drug related and was completely cured. This was the only malignancy reported during the study.

Two patients developed diabetes mellitus during the course of the treatment; however, this was not considered a drug-related event. The mean level of glucose (Fig. 1a) and glycosylated haemoglobin (HbA1c; Fig. 1b) remained unchanged throughout the study period.

Effectiveness

Body composition changed with Omnitrope® treatment, with slight increases seen in most of the anthropometric parameters investigated over the treatment period; however, none of these were significant (Table 3).

There was no apparent change in lipid levels over the study duration. A slight decrease in low-density lipoprotein (LDL) cholesterol levels was observed over the duration of the study (Fig. 2a), whereas the ratio of high-density lipoprotein (HDL)/LDL cholesterol over time did not significantly change (Fig. 2b).

In the first 6 months of Omnitrope® therapy, IGF-1 values increased significantly from baseline in patients who had not received a previous rhGH (Fig. 3). Over the remainder of the study, IGF-1 values remained relatively stable (Fig. 3).

Discussion

The results of this interim analysis show that Omnitrope® is well tolerated in Italian adults with GHD. The most common AEs reported were arthralgia, asthenia and insomnia, and SAEs were reported in 14.9% of patients. These safety data are consistent with the safety profile of Omnitrope® observed in all patients included in the PATRO Adults study, which has been presented at international conferences in 2013, 2014 and 2015 [10–12]. These reports indicate that Omnitrope® was well tolerated in real-life practice with no confirmed cases of drug-related diabetes, reports of malignancy or other safety issues. The safety profile of Omnitrope® is similar in both

### Table 1 (continued)

| Characteristic            | N=67 |
|---------------------------|------|
| Duration of Omnitrope® treatment, months | 45.4 ± 24.3 |

All values are presented as mean ± standard deviation unless otherwise stated

BMI body mass index, GHD growth hormone deficiency, SD standard deviation

Normal onset of puberty was considered 8–13 years of age in girls and 9–14 years of age in boys; late onset of puberty was considered >13 years of age in girls and >14 years of age in boys

### Table 2 Adverse events in the SAF (n=67)

| Events, n | Patients, n (%) |
|-----------|-----------------|
| Any AE     | 89              | 37 (55.2)     |
| Relationship to study drug | Not suspected | 83 | 35 (52.2) |
| Intensity  |                 |               |
| Mild       | 54              | 33 (49.3)     |
| Moderate   | 32              | 16 (23.9)     |
| Severe     | 3               | 3 (4.5)       |
| Outcome    |                 |               |
| Resolved completely | 40 | 22 (32.8) |
| Resolved with sequelae | 3 | 3 (4.5) |
| Ongoing    | 46              | 25 (37.3)     |
| Medication given | No | 67 | 30 (44.8) |
| Yes        | 21              | 17 (25.4)     |
| Missing    | 1               | 1 (1.5)       |
| Changes to Omnitrope® | Not changed | 76 | 33 (49.3) |
| Reduced    | 3               | 2 (3.0)       |
| Interrupted| 8               | 5 (7.5)       |
| Missing    | 2               | 1 (1.5)       |
| SAE        | 14              | 10 (14.9)     |
| AEs in ≥2 patients, n (%) | Arthralgia | – | 6 (9.0) |
| Asthenia   | –               | 5 (7.5)       |
| Insomnia   | –               | 4 (6.0)       |
| Headache   | –               | 3 (4.5)       |
| Back pain  | –               | 2 (3.0)       |
| Hypokalaemia| –              | 2 (3.0)       |
| Muscle spasms | –         | 2 (3.0)       |
| Myalgia    | –               | 2 (3.0)       |
| Osteopenia | –               | 2 (3.0)       |
| Paraesthesia| –             | 2 (3.0)       |
| Weight increased | – | 2 (3.0) |

AEs adverse events, SAE serious adverse event
adults naïve to rhGH and patients previously treated with other rhGH formulations.

The link between patients receiving replacement rhGH therapy and the possibility of developing diabetes has been a concern, with anecdotal reports of a cause and effect relationship. The incidence of metabolic syndrome is higher in patients with GHD compared with reference populations [14, 15]. However, there are conflicting reports regarding the effect of GH replacement on glucose metabolism. Some studies have shown that rhGH treatment may accelerate the onset of diabetes in predisposed paediatric individuals and patients receiving rhGH therapy may have an increased
incidence of metabolic abnormalities in the long term [16–19]. Conversely, other authors have found no evidence to support an increase in the onset of diabetes mellitus in rhGH-treated patients [16, 20]. The results emerging from this analysis seem to confirm that no link exists between adequate rhGH replacement therapy in adults with GHD and the development of diabetes. In fact, no significant changes in glucose metabolism were recorded in the entire cohort of patients, while in the two cases that developed diabetes mellitus during the study, this was not considered drug-related.

Patients with GHD tend to have increased LDL and decreased HDL cholesterol levels, with both features considered characteristic of metabolic syndrome [3]. However, some studies have suggested that rhGH replacement therapy may reverse this trend, increasing the level of HDL and decreasing the level of LDL [3]. Although the sample size is too small to be conclusive, in the Italian GHD population evaluated in the present study, there was a slight decrease in the level of LDL during treatment with Omnitrope®.

As both GH and IGF-1 have mitogenic properties, there is concern that rhGH therapy could increase the risk of developing malignant diseases in treated patients. So far, there is no evidence from the Italian GHD patients included in the PATRO Adults study that rhGH therapy increases the risk of malignancy as only one case was reported, which was not thought to be drug related. These results are consistent with several other studies, which also suggest that adequate replacement therapy with rhGH does not increase the risk of de novo or recurring tumours [21–25].

These results are also in line with other studies which explored the efficacy of Omnitrope® [7, 8]. While the results of this analysis are supportive of those from the long-term interventional trials of rhGH for the treatment of adults with GHD, there are some limitations in the interpretation of these findings. The number of patients included in this interim analysis over the long term was small and unselected, which may bias the results. Nonetheless, despite these limitations we believe that this study is reflective of real-world clinical practice in Italy and may be interpreted as such.

It is of interest to compare our findings with the data collected by the global PATRO Adults study [26]. The results of this analysis are consistent with the latest data of the overall PATRO Adults study, which was analysed in September 2015 (data on file). In the 954 patients recruited so far [mean (SD) age 50.2 (15.2) years; mean (SD) BMI 29.4 (6.1) kg/m²], 515 (54%) have been pre-treated with another rhGH. Overall, 1497 AEs have been reported in 473 (49.6%) patients; 245 of these were considered serious. There were 110 ADRs in 68 patients, including 19 general disorders/administration site conditions, 18 nervous system disorders, 16 musculoskeletal/connective tissue disorders and two events of increased IGF-1 levels. A total of 23 SAEs in 16 patients were suspected to be related to treatments, including one case.

**Table 3** Change in body composition in the EFF

| Anthropometric parameter | Waist circumference, cm | Lean body mass | Total fat mass | Weight, kg | BMI, kg/m² |
|--------------------------|-------------------------|---------------|---------------|------------|------------|
| N | Mean ± SD | N | Mean ± SD | N | Mean ± SD | N | Mean ± SD |
| Baseline | 18 | 94.6 ± 14.4 | 9 | 57.55 ± 7.03 | 10 | 35.3 ± 9.4 | 46 | 80.4 ± 19.0 | 46 | 28.8 ± 5.7 |
| 0.5 years | 7 | 98.8 ± 24.3 | 1 | – | 1 | – | 18 | 80.7 ± 23.5 | 15 | 27.9 ± 5.9 |
| 1.0 years | 17 | 94.5 ± 15.4 | 5 | 63.9 ± 8.6 | 5 | 35.4 ± 7.5 | 36 | 87.1 ± 18.5 | 31 | 28.9 ± 5.4 |
| 1.5 years | 14 | 97.8 ± 13.7 | 5 | 59.6 ± 5.8 | 7 | 36.1 ± 7.2 | 31 | 82.20 ± 23.1 | 25 | 29.0 ± 6.3 |
| 2.0 years | 9 | 95.7 ± 9.4 | 0 | – | 0 | – | 30 | 76.9 ± 19.1 | 22 | 27.0 ± 4.4 |
| 2.5 years | 6 | 89.7 ± 10.0 | 0 | – | 0 | – | 22 | 79.2 ± 18.3 | 17 | 28.1 ± 4.3 |
| 3.0 years | 5 | 90.2 ± 9.7 | 1 | – | 2 | 40.9 ± 0.3 | 20 | 72.5 ± 11.7 | 14 | 26.6 ± 4.2 |
| 3.5 years | 10 | 97.9 ± 14.1 | 3 | 65.2 ± 1.3 | 6 | 37.8 ± 6.3 | 18 | 76.9 ± 16.5 | 15 | 27.9 ± 4.0 |
| 4.0 years | 6 | 105.5 ± 18.5 | 1 | – | 1 | – | 22 | 77.2 ± 16.2 | 21 | 27.5 ± 3.9 |
| 4.5 years | 2 | 90.5 ± 2.1 | 0 | – | 0 | – | 15 | 72.4 ± 15.4 | 13 | 27.0 ± 4.7 |
| 5.0 years | 4 | 94.5 ± 10.7 | 2 | 45.4 ± 34.5 | 3 | 39.1 ± 7.8 | 16 | 75.2 ± 11.7 | 14 | 27.3 ± 4.1 |
| 5.5 years | 3 | 96.2 ± 5.8 | 1 | – | 4 | 37.6 ± 6.4 | 9 | 72.6 ± 12.6 | 8 | 27.2 ± 2.3 |
| 6.0 years | 2 | 88.3 ± 4.6 | 1 | – | 2 | 38.5 ± 1.6 | 10 | 81.2 ± 13.5 | 9 | 29.3 ± 5.2 |
| 6.5 years | 1 | – | 0 | – | 0 | – | 7 | 88.5 ± 12.0 | 7 | 26.2 ± 3.7 |
| 7.0 years | 0 | – | 0 | – | 0 | – | 2 | 74.0 ± 14.6 | 2 | 27.7 ± 4.2 |

BMI body mass index, N number of patients
1 of: worsening of diabetes mellitus, dyspnoea and multiple endocrine neoplasia type 1. Of the 105 patients who discontinued treatment, 23 (21.9%) patients discontinued due to an AE.

In conclusion, this preliminary analysis shows that, as with other rhGHs, treatment with Omnitrope® is well tolerated in adult patients with GHD in routine clinical practice, with no confirmed relationship with the
development of diabetes, no occurrence of malignancy or other additional safety issues. This analysis also confirms the effectiveness of Omnitrope® for the treatment of adults with GHD.

Acknowledgements  Medical writing assistance in drafting the outline and first draft for this manuscript was provided by Simone Boni-face and Cécile Duchesnes, PhD, of Springer Healthcare Communications. This assistance was funded by, Sandoz S. P. A., Italy.

The authors would like to acknowledge the contribution of all the Italian investigators and co-investigators: Mara Boschet1, Mir-yam Talco1, Claudia Giavoli2, Ezio Ghigo3, Ettore Degli Uberti4, Maria Chiara Zatelli6, Marta Bondanelli6, Elisa Stefanetti6, Gemma Fraterrigo6, Marianna Martino1, Grazia Michetti7, Roberto Vettor8, Anna Spada11.

Sandoz would also like to acknowledge the contribution of the MAPI Group for their work as the contract research organization for this study, in particular the contributions of Stefania Lamartina, Mohamed El Sayed and Giulia Biagioli.
Compliance with ethical standards

Conflict of interest P. Beck-Peccoz is a member of the PATRO Adults Monitoring Committee supported by Sandoz; E. Zecchi and A. Pietropoli are employees of Sandoz; all the other Authors declare no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ho KK (2007) Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157(6):695–700. doi:10.1530/EJE-07-0631
2. Gupta V (2011) Adult growth hormone deficiency. Indian J Endocrinol Metab 15(Suppl 3):S197–S202. doi:10.4103/2230-8210.84865
3. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(6):1587–1609. doi:10.1210/jc.2011-0179
4. Reed ML, Merriam GR, Kargi AY (2013) Adult growth hormone deficiency—benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne) 4:64. doi:10.3389/fendo.2013.00064
5. Boschetti M, Agosti S, Albanese V, Casalino L, Teti C, Bezante GP, Brunelli C, Albertelli M, Feron D (2016) One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. Endocr. doi:10.1007/s12020-016-0951-4
6. European Medicines Agency Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 5 April 2016
7. Thakrar K, Bodalia P, Grosso A (2010) Assessing the efficacy and safety of Omnitrope. Br J Clin Pharm 2(10):298–301
8. Ullah A, Peacock H, Arutchelvam V, Nag S, Ashwell S (2012) The cost, efficacy and safety of Omnitrope compared with Genotropin in adults with growth hormone deficiency. Presented at BES 2012; 18–22 March 2012; Harrogate, UK. Endocrine Abstracts 28:PS2
9. Beck-Peccoz P, Minuto F, Leal-Cerro A, Zabransky M, Stalla G (2012) Rationale and design of PATRO Adults, a multicentre, non-interventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with GH deficiency. Ther Adv Endocrinol Metab 3(3):85–91. doi:10.1177/204218181244152
10. Beck-Peccoz P, Höbye C, Murray RD, Simsek S, Leal-Cerro A, Zabransky M, Stalla G (2015) The PATRO adult study of Omnitrope® for the treatment of adult patients with GH deficiency: latest results [abstract]. Presented at the 17th European Congress of Endocrinology (ESE 2015); 16–20 May 2015; Dublin, Ireland. Endocrine Abstracts 37:EP665
11. Stalla G, Leal-Cerro A, Simsek S, Minuto F, Zabransky M, Beck-Peccoz P (2013) First results from the PATRO adults study of Omnitrope for the treatment of adult patients with GH deficiency [abstract]. Presented at the 15th European Congress of Endocrinology (ECE 2013); April 27-May 1, 2013; Copenhagen, Denmark. Endocrine Abstracts 32:PS630
12. Beck-Peccoz P, Höbye C, Murray RD, Simsek S, Leal-Cerro A, Minuto F, Zabransky M, Stalla G (2014) The PATRO Adults study of Omnitrope® for the treatment of adult patients with growth hormone deficiency: latest results [abstract]. Presented at the 16th International Congress of Endocrinology and the Endocrine Society’s 96th Annual Meeting & Expo (ICE/ENDO 2014); 21–24 June 2014; Chicago, IL, USA. Poster SAT-0693
13. European Medicines Agency (2011) Omnitrope® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000607/WC00043695.pdf. Accessed 19 Nov 2015.
14. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95(1):74–81. doi:10.1210/jc.2009-1326
15. Verhelst J, Mattsson AF, Luger A, Thunander M, Göth M, Kolowska-Häggström M, Abs R (2011) Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 165(6):881–889. doi:10.1530/EJE-11-0599
16. Attanasio AF, Jung H, Mo D, Chanson P, Bouillou R, Ho KK, Lamberts SW, Clemmons DR (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 96(7):2255–2261. doi:10.1210/jc.2011-0448
17. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, Biermasz NR, Pereira AM (2013) Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rGh) therapy. J Clin Endocrinol Metab 98(1):352–361. doi:10.1210/jc.2012-2940
18. Cutfield WS, Wilton P, Benmarker H, Albertsson-Wikland K, Chatelan P, Ranke MB, Price DA (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth hormone treatment. The Lancet 355(9204):610–613. doi:10.1016/S0140-6736(99)04055-6
19. Prokta E, Giavoli C, Bergamaschi S, Ferrante E, Malchiodi E, Sala E, Verrua E, Rodari G, Filopanti M, Beck-Peccoz P, Spada A (2015) Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma. J Endocrinol Invest 38(4):413–420. doi:10.1007/s12020-016-0951-4
20. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO (2002) Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87(5):2121–2127. doi:10.1210/jcem.87.5.8482
21. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL (2002) Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol 146(6):807–811
22. Frajese G, Drake WM, Loureiro RA, Evanson J, Coyle D, Wood DF, Grossman AB, Besser GM, Monson JP (2001) Hypothalamic-pituitary surveillance imaging in hypopituitary patients.
receiving long-term GH replacement therapy. J Clin Endocrinol Metab 86(11):5172–5175. doi:10.1210/jcem.86.11.8018
23. Buchfelder M, Kann PH, Wüster C, Tschty U, Saller B, Brabant G, Kleindienst A, Nomikos P (2007) Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur J Endocrinol 157(2):149–156. doi:10.1530/EJE-07-0164
24. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 165(2):217–223. doi:10.1530/EJE-11-0286
25. Brignardello E, Felicetti F, Castiglione A, Fortunati N, Matarazzo P, Biasin E, Sacerdote C, Ricardi U, Fagioli F, Corrias A, Arvat E (2015) GH replacement therapy and second neoplasms in adult survivors of childhood cancer: a retrospective study from a single institution. J Endocrinol Invest 38(2):171–176. doi:10.1007/s40618-014-0179-1
26. Stalla G, Beck-Peccoz P, Hoybye C, Murray RD, Simsek S, Leal-Cerro A, Zabrisky M. The PATRO Adults study of Omnitrope® for the treatment of adult patients with growth hormone deficiency: latest results. Presented at the 2016 Endocrine Societies’ Annual Meeting (ENDO 2016); 1–4 April 2016; Boston, MA, USA